KeyBanc raised the firm’s price target on Emerson (EMR) to $185 from $155 and keeps an Overweight rating on the shares following quarterly results. The firm was encouraged by Emerson’s solid Q1 2026 organic order growth, which it thinks supports potential upside to FY27 estimates.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EMR: